{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    45
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_2",
        "affectedSection": "Sections 3.1.1, 3.1.1.1, 4.1, 6, 6.1, 9.5",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Increase in patient sample size to ensure adequate power for the primary endpoint."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_2",
        "affectedSection": "Section 2.6",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addition of language allowing for exploratory substudies."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_2",
        "affectedSection": "Section 3.1.2 and Appendix 1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarification on obtaining missed PK, PD, or ADA samples at the next scheduled visit."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_2",
        "affectedSection": "Section 4.3.3",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated IMP transit temperature monitoring requirements."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_2",
        "affectedSection": "Section 5.4.1",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Update of Medical Monitors and Emergency Medical Contacts."
      },
      {
        "id": "impact_6",
        "amendmentId": "amend_2",
        "affectedSection": "Section 5.4.3.1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Inclusion of pregnancy reporting instructions for female patients in the ICF."
      },
      {
        "id": "impact_7",
        "amendmentId": "amend_2",
        "affectedSection": "Section 6.2.5 and 6.2.7",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarification of faricimab-pooled safety and immunogenicity analysis populations."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_2",
        "reasonText": "Mitigate loss of patients/data and potential impact of protocol deviations due to extenuating circumstances like the COVID-19 pandemic.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_2",
        "reasonText": "To allow the Sponsor to propose exploratory substudies associated with the protocol.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_2",
        "reasonText": "Improve clarity and consistency of study procedures and population definitions.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.1.1",
        "beforeText": "Not specified in summary",
        "afterText": "Increased sample size",
        "summary": "Sample size increased to ensure adequate power for primary endpoint efficacy analyses."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_2",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.6",
        "beforeText": "null",
        "afterText": "Language to allow Sponsor to propose exploratory substudies",
        "summary": "Added provision for exploratory substudies."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_2",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.1.2",
        "beforeText": "Not specified in summary",
        "afterText": "Missed mandatory PK, PD, or ADA samples may be obtained at the next scheduled visit",
        "summary": "Clarified handling of missed laboratory samples."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.3.3",
        "beforeText": "Not specified in summary",
        "afterText": "Sites can confirm temperature conditions via time monitoring or temperature monitoring",
        "summary": "Updated IMP transit monitoring options."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_2",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4.3.1",
        "beforeText": "null",
        "afterText": "ICF will instruct female patients to inform the investigator if they become pregnant",
        "summary": "Added pregnancy notification requirement to ICF language."
      },
      {
        "id": "change_6",
        "amendmentId": "amend_2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.6",
        "beforeText": "Incorrect Roche policy name",
        "afterText": "Corrected Roche policy name",
        "summary": "Corrected the name of the Roche policy on data sharing."
      }
    ],
    "summary": {
      "impactCount": 7,
      "reasonCount": 3,
      "changeCount": 6
    }
  }
}